info@seagull-health.com
SeagullHealth
语言:
search
How well does Alpelisib(PIQRAY) work?
A summary of the clinical trial results demonstrating the drug's effectiveness.
Clinical Benefits
In the SOLAR-1 trial, PIQRAY plus fulvestrant demonstrated a statistically significant improvement in progression-free survival (PFS) compared to placebo plus fulvestrant in patients with PIK3CA-mutated tumors. The median PFS was 11.0 months vs. 5.7 months. The combination also showed a higher overall response rate (ORR) of 35.7% compared to 16.2% in the placebo arm.
Related Columns
Alpelisib(PIQRAY)
PIQRAY is indicated in combination with fulvestrant for the treatment of...
WeChat Scan
Free Inquiry
Free Inquiry
共 1 条
- 1
Departments
New Articles
New Drugs
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
Contact Us
- haiousales@gmail.com
Welcome to consult
Seagull Pharmacy.,Ltd All rights reserved